Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Human antibodies from transgenic animals.

Nils Lonberg1

  • 1Medarex, 521 Cottonwood Drive, Milpitas, California 95035, USA. nlonberg@medarex.com

Nature Biotechnology
|September 10, 2005
PubMed
Summary

Transgenic mice producing human antibody sequences enable the development of therapeutic monoclonal antibodies (mAbs) with reduced immunogenicity. Clinical trials show promise, but regulatory approval is key to validating this drug discovery tool.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Naturally self-reactive B cells are poised to cross the selection barrier into autoimmune germinal centers.

Cell reports·2026
Same author

The Problem with Syngeneic Mouse Tumor Models.

Cancer immunology research·2025
Same author

Modulating the immunodominance hierarchy of immunoglobulin germline-encoded structural motifs targeting the influenza hemagglutinin stem.

Cell reports·2024
Same author

Engaging an HIV vaccine target through the acquisition of low B cell affinity.

Nature communications·2023
Same author

An epitope-enriched immunogen expands responses to a conserved viral site.

Cell reports·2022
Same author

Allelic polymorphism controls autoreactivity and vaccine elicitation of human broadly neutralizing antibodies against influenza virus.

Immunity·2022

Area of Science:

  • Biotechnology
  • Immunology
  • Pharmacology

Background:

  • Laboratory mice are a source of high-affinity monoclonal antibodies (mAbs).
  • Rodent antibody immunogenicity hinders their therapeutic development.
  • Transgenic mice expressing human antibody genes offer a solution to reduce immunogenicity.

Purpose of the Study:

  • To evaluate the potential of transgenic mice for generating low-immunogenicity therapeutic mAbs.
  • To assess the clinical progress and challenges of human sequence mAbs derived from transgenic mice.
  • To explore future applications of transgenic animal technology for polyclonal sera production.

Main Methods:

  • Utilizing transgenic mice engineered with human antibody gene sequences.
  • Developing therapeutic monoclonal antibodies (mAbs) from these engineered mice.
  • Monitoring clinical trials of drugs containing variable regions from transgenic mouse-derived human sequences.

Main Results:

  • Over a dozen companies utilize this technology for therapeutic mAb development.
  • At least 33 drugs with human sequences from transgenic mice are in clinical trials.
  • Emerging trial data offer initial insights into safety and efficacy.

Conclusions:

  • Transgenic mouse technology is a promising tool for developing therapeutic monoclonal antibodies (mAbs).
  • Clinical trial data suggest potential but require further validation through product approval.
  • Future applications may include using transgenic farm animals for polyclonal sera generation.

Related Experiment Videos